Impact of Continuous Renal Replacement Therapy on Bivalirudin Dosing in Pediatric Extracorporeal Membrane Oxygenation

• Published in: ASAIO journal (1992) Vol. 68; no. 11; p. 1393
• Main Authors: Lahart, Michael A, Burns, Emily L, Streb, Madison M, Gu, Hongjie, Neumayr, Tara M, Abarbanell, Aaron M, Said, Ahmed S
• Format: Journal Article
• Language: English
• Published: United States 01.11.2022
• Subjects: Continuous Renal Replacement Therapy; Extracorporeal Membrane Oxygenation; Hirudins - administration & dosage; Humans; Infant; Peptide Fragments - administration & dosage; Renal Replacement Therapy; Retrospective Studies
• ISSN: 1538-943X
• DOI: 10.1097/MAT.0000000000001681

There is an increasing interest in the use of bivalirudin for pediatric extracorporeal membrane oxygenation (ECMO) anticoagulation. However, dosing is not well described in those requiring continuous renal replacement therapy (CRRT). We aimed to determine whether CRRT affects bivalirudin dosing in pediatric ECMO patients. Children ≤18 years of age placed on ECMO and anticoagulated with bivalirudin for ≥24 hours from January 2019 to May 2020 were included. Bivalirudin doses were collected for 144 hours from initiation of bivalirudin or CRRT. Analysis was performed to determine whether CRRT, age, or weight affected bivalirudin dosing. Thirty-one children were included, and 11 (35%) required concomitant CRRT. There was no difference in age (median 9.1 versus 3.2 months, p = 0.15) or days on ECMO (median 11 versus 9, p = 0.7) between those who did or did not receive CRRT. The mean bivalirudin dosing was similar in patients who did or did not require CRRT (median and IQR: 0.13 mg/kg/hour [0.08-0.26] versus 0.15 mg/kg/hour [0.11-0.22], respectively, p = 0.13). Younger age ( p < 0.001) and lower weight ( p < 0.001) were associated with higher bivalirudin dosing. In our study, bivalirudin dosing did not differ if the patient required CRRT while on ECMO.